Retrospective population-based study of contemporary incidence and survival of lung neuroendocrine neoplasms

A retrospective population-based cohort study in Ontario found that the incidence of lung neuroendocrine neoplasms (NENs) increased 2.87-fold from 2000 to 2020, primary due to typical neuroendocrine tumors (NETs) and stage I disease. Ten-year overall survival rate was 40%, varying by histology and stage; for typical NETs and stage I tumors, non-cancer-related mortality exceeded lung cancer death within 2 and 3 years, respectively. The authors conclude that these findings highlight the evolving epidemiology of lung NENs and suggest that tailoring surveillance and treatment strategies based on tumor subtype and risk of competing mortality are crucial.